September 3, 2009 (FinancialWire) — Abbott (NYSE: ABT) said it has signed a definitive agreement to acquire privately-held Visiogen, Inc. for $400 million in cash.

Irvine, California-based Visiogen, which has European operations in Karlsruhe, Germany, is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts.

In a statement, Abbott said that the acquisition of Visiogen will provide it with a “next-generation” accommodating intraocular lens technology to address presbyopia for cataract patients.

The transaction is scheduled to close in the fourth quarter of 2009. Abbot said that the transaction does not impact its previously issued earnings-per-share guidance for 2009.

Abbot Park, Illinois-based Abbott is a health care company focused on the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

The company employs more than 72,000 people and markets its products in more than 130 countries.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.